PT1465653E - Aplicação terapêutica do g-csf, do gm-csf e do scf - Google Patents

Aplicação terapêutica do g-csf, do gm-csf e do scf Download PDF

Info

Publication number
PT1465653E
PT1465653E PT03712209T PT03712209T PT1465653E PT 1465653 E PT1465653 E PT 1465653E PT 03712209 T PT03712209 T PT 03712209T PT 03712209 T PT03712209 T PT 03712209T PT 1465653 E PT1465653 E PT 1465653E
Authority
PT
Portugal
Prior art keywords
csf
group
rats
days
test
Prior art date
Application number
PT03712209T
Other languages
English (en)
Inventor
Didier Pourquier
Didier Moukoko
Original Assignee
Didier Pourquier
Didier Moukoko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Didier Pourquier, Didier Moukoko filed Critical Didier Pourquier
Publication of PT1465653E publication Critical patent/PT1465653E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PT03712209T 2002-01-18 2003-01-06 Aplicação terapêutica do g-csf, do gm-csf e do scf PT1465653E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200610A FR2834898B1 (fr) 2002-01-18 2002-01-18 Nouvelle application therapeutique du g-csf, du gm-csf et du scf

Publications (1)

Publication Number Publication Date
PT1465653E true PT1465653E (pt) 2011-10-18

Family

ID=27589516

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03712209T PT1465653E (pt) 2002-01-18 2003-01-06 Aplicação terapêutica do g-csf, do gm-csf e do scf

Country Status (8)

Country Link
EP (2) EP1465653B1 (pt)
AT (1) ATE519496T1 (pt)
DK (1) DK1465653T3 (pt)
ES (2) ES2389244T3 (pt)
FR (1) FR2834898B1 (pt)
PT (1) PT1465653E (pt)
SI (1) SI1465653T1 (pt)
WO (1) WO2003061685A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. 血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004058287A2 (en) * 2002-12-31 2004-07-15 Axaron Bioscience Ag Methods of treating neurological conditions with hematopoeitic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4891477B2 (ja) * 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. 血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
US20040120925A1 (en) * 2001-03-12 2004-06-24 Masahiro Toda Remedies for nerve damages

Also Published As

Publication number Publication date
ES2370290T3 (es) 2011-12-14
FR2834898A1 (fr) 2003-07-25
FR2834898B1 (fr) 2005-06-10
ES2389244T3 (es) 2012-10-24
EP2277529B1 (fr) 2012-06-06
EP1465653B1 (fr) 2011-08-10
WO2003061685A1 (fr) 2003-07-31
SI1465653T1 (sl) 2011-11-30
DK1465653T3 (da) 2011-10-17
EP1465653A1 (fr) 2004-10-13
ATE519496T1 (de) 2011-08-15
EP2277529A1 (fr) 2011-01-26

Similar Documents

Publication Publication Date Title
SI1465653T1 (sl) Terapevtska raba G-CSF
AU2002223302B2 (en) Treatment of statin side effects
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
EP2548880A3 (en) Compositions for increasing telomerase activity
EP1671627B8 (en) Improvement of cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves
DE3519361A1 (de) (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
WO2012065651A1 (en) A synergistic composition of plant extracts for treating skin diseases involving abnormal cell growth
US20170065679A1 (en) Treatment of diabetes using g-csf
WO2002069980A2 (en) Pharmaceutically effective ginsenosides and their use
EP1276497B1 (en) Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
Goldberg et al. Role of hyaluronidase in the regulation of functions of mesenchymal precursor cells
CA2563800A1 (en) Spinosyns for wound healing
AU2001258322A1 (en) Formulation having mobilising activity
Austin et al. The beneficial effects of immunostimulation in posttraumatic sepsis
PT814828E (pt) Metodo de fabrico de um agente terapeutico para a regeneracao de oligodendrocitos
CA2332935A1 (en) A method for inducing production of growth factors
Bashey et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation
Zucali et al. Hematopoietic effects of interleukin-1
EP3217975B1 (de) Verwendung von immunmodulatorisch wirksamen zusammensetzungen zur immuntherapeutischen behandlung von patienten mit myeloischen leukämien
Takahashi et al. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia
Haan et al. Microenvironmentally dependent effects on murine haemopoiesis by a prolonged interleukin‐1 treatment
Ku et al. Tinggong (SI 19), a novel acupoint for 2Hz electroacupuncture-induced depressor response
Fedoročko et al. Administration of the bacterial extract Broncho-Vaxom® enhances radiation recovery and myelopoietic regeneration
CN1589904A (zh) 造血干细胞动员剂制备治疗糖尿病药物的用途